文献速递创伤与烧伤复苏、休克与脓毒症

院前输注冻干血浆治疗创伤性凝血病:一项随机临床试验

Prehospital Lyophilized Plasma Transfusion for Trauma-Induced Coagulopathy in Patients at Risk for Hemorrhagic Shock: A Randomized Clinical Trial.
PubMed 文献 · JAMA Netw Open · 2022-07-01
一句话结论在失血性休克高危创伤患者中,院前输注冻干血浆与生理盐水标准治疗相比,入院时INR无显著差异,但该操作可行且安全。

这项在法国多中心院前急救团队中开展的随机临床试验,纳入150例有失血性休克及相关凝血病风险的成人创伤患者,1:1随机接受冻干血浆输注或生理盐水标准治疗。主要终点为入院时INR,血浆组中位INR 1.21 vs 对照组1.20(中位差值-0.01,P=.88),无显著差异。大量输血需求(7例[10.3%] vs 4例[6.1%],RR 1.78,P=.37)和30天生存(死亡HR 1.07,P=.89)亦无显著差异。作者认为冻干血浆院前输注在该人群中是可行且安全的操作。

要点

  • 在失血性休克高危创伤患者中,院前冻干血浆输注与生理盐水相比,入院时INR无显著差异(中位1.21 vs 1.20,中位差值-0.01,P=.88)。
  • 大量输血需求在血浆组为7例(10.3%),对照组为4例(6.1%),RR 1.78(95%CI 0.42-8.68),P=.37,无显著差异。
  • 30天生存的死亡HR为1.07(95%CI 0.44-2.61),P=.89,两组无显著差异。
  • 在意向治疗全人群(n=150)中,预设不良事件(血栓形成、输血相关急性肺损伤、输血相关循环超负荷)发生率两组无差异。
  • 作者认为,冻干血浆院前输注对于该患者人群是可行且安全的操作。

适用人群与场景

  • 法国多中心院前急救团队接诊的成人创伤患者,有失血性休克及相关凝血病风险,于2016年4月1日至2019年9月30日纳入,随访28天。

处置流程与药物剂量

  • 患者按1:1随机接受冻干血浆输注或生理盐水输注(标准治疗,对照组)。

研究设计与关键结果

  • 研究类型:随机临床试验,法国多中心,纳入150例成人创伤患者,1:1随机分为血浆组与生理盐水对照组。
  • 主要终点:入院时INR,血浆组中位1.21(IQR 1.12-1.49)vs 对照组1.20(IQR 1.10-1.39),中位差值-0.01(IQR -0.09至0.08),P=.88。
  • 次要终点:大量输血需求血浆组7例(10.3%)vs 对照组4例(6.1%),RR 1.78(95%CI 0.42-8.68),P=.37;30天生存死亡HR 1.07(95%CI 0.44-2.61),P=.89。
  • 安全性:意向治疗全人群(n=150)中,预设不良事件(血栓形成、输血相关急性肺损伤、输血相关循环超负荷)发生率两组无差异。
  • 分析人群:150例随机患者中134例纳入分析(中位年龄34岁[IQR 26-49],男性110例[82.1%]),血浆组68例,对照组66例。

证据类型、等级与局限

  • 证据类型:随机临床试验。
  • 作者结论:院前输注冻干血浆与生理盐水标准治疗相比,INR值无显著差异;但冻干血浆输注对该患者人群是可行且安全的操作。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对于有失血性休克及相关凝血病风险的创伤患者,院前输注冻干血浆未显示能改善入院时INR、大量输血需求或30天生存,但作者认为该操作可行且安全。
  • 作者认为冻干血浆院前输注可作为该患者人群的可行且安全的操作。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Blood transfusion is a mainstay of therapy for trauma-induced coagulopathy, but the optimal modalities for plasma transfusion in the prehospital setting remain to be defined.

OBJECTIVE: To determine whether lyophilized plasma transfusion can reduce the incidence of trauma-induced coagulopathy compared with standard care consisting of normal saline infusion.

DESIGN, SETTING, AND PARTICIPANTS: This randomized clinical trial was performed at multiple centers in France involving prehospital medical teams. Participants included 150 adults with trauma who were at risk for hemorrhagic shock and associated coagulopathy between April 1, 2016, and September 30, 2019, with a 28-day follow-up. Data were analyzed from November 1, 2019, to July 1, 2020.

INTERVENTION: Patients were randomized in a 1:1 ratio to receive either plasma or standard care with normal saline infusion (control).

MAIN OUTCOMES AND MEASURES: The primary outcome was the international normalized ratio (INR) on arrival at the hospital. Secondary outcomes included the need for massive transfusion and 30-day survival. As a safety outcome, prespecified adverse events included thrombosis, transfusion-related acute lung injury, and transfusion-associated circulatory overload.

RESULTS: Among 150 randomized patients, 134 were included in the analysis (median age, 34 [IQR, 26-49] years; 110 men [82.1%]), with 68 in the plasma group and 66 in the control group. Median INR values were 1.21 (IQR, 1.12-1.49) in the plasma group and 1.20 (IQR, 1.10-1.39) in the control group (median difference, -0.01 [IQR, -0.09 to 0.08]; P = .88). The groups did not differ significantly in the need for massive transfusion (7 [10.3%] vs 4 [6.1%]; relative risk, 1.78 [95% CI, 0.42-8.68]; P = .37) or 30-day survival (hazard ratio for death, 1.07 [95% CI, 0.44-2.61]; P = .89). In the full intention-to-treat population (n = 150), the groups did not differ in the rates of any of the prespecified adverse events.

CONCLUSIONS AND RELEVANCE: In this randomized clinical trial including severely injured patients at risk for hemorrhagic shock and associated coagulopathy, prehospital transfusion of lyophilized plasma was not associated with significant differences in INR values vs standard care with normal saline infusion. Nevertheless, these findings show that lyophilized plasma transfusion is a feasible and safe procedure for this patient population.

TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02736812.

来源:JAMA Netw Open,查看原文。版权归原作者所有。

参考来源

  1. Jost D, Lemoine S, Lemoine F, et al. Prehospital Lyophilized Plasma Transfusion for Trauma-Induced Coagulopathy in Patients at Risk for Hemorrhagic Shock: A Randomized Clinical Trial. JAMA Netw Open. 2022. PMID: 35881397. doi:10.1001/jamanetworkopen.2022.23619

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。